The purpose of this clinical trial is to learn if the study drug ropeginterferon alfa- 2b added to, standard of care, ruxolitinib is safe and effective in treating patients with Myelofibrosis.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
The frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by type
Timeframe: 2 years
The frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by severity (as defined by the NIH CTCAE, version 6.0).
Timeframe: 2 years
The frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by seriousness.
Timeframe: 2 years
The frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by duration.
Timeframe: 2 years
The frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by the relationship to study treatment.
Timeframe: 2 years